This Article Full Text Full Text (PDF) All Versions of this Article: 95/2/217    most recent 01.RES.0000134628.96682.9bv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beckman, J. A. Articles by Creager, M. A. Search for Related Content PubMed PubMed Citation Articles by Beckman, J. A. Articles by Creager, M. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATORVASTATIN CHOLESTEROL HEPTANOIC ACID L-TYROSINE PYRROLE Medline Plus Health Information Smoking Related Collections Lipid and lipoprotein metabolism Endothelium/vascular type/nitric oxide Pathophysiology Risk Factors

(Circulation Research. 2004;95:217.)
© 2004 American Heart Association, Inc.

Clinical Research

Atorvastatin Restores Endothelial Function in Normocholesterolemic Smokers Independent of Changes in Low-Density Lipoprotein

Joshua A. Beckman, James K. Liao, Shauna Hurley, Leslie A. Garrett, Daoshan Chui, Debi Mitra, Mark A. Creager

From Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.

Correspondence to Mark A. Creager, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail mcreager{at}partners.org

Cigarette smoking impairs endothelial function. Hydroxymethylglutaryl (HMG) CoA reductase inhibitors (statins) may favorably affect endothelial function via nonlipid mechanisms. We tested the hypothesis that statins would improve endothelial function independent of changes in lipids in cigarette smokers. Twenty normocholesterolemic cigarette smokers and 20 matched healthy control subjects were randomized to atorvastatin 40 mg daily or placebo for 4 weeks, washed out for 4 weeks, and then crossed-over to the other treatment. Baseline low-density lipoprotein (LDL) levels were similar in smokers and healthy subjects, 103±22 versus 95±27 mg/dL, respectively (P=NS) and were reduced similarly in smokers and control subjects by atorvastatin, to 55±30 and 58±20 mg/dL, respectively (P=NS). Vascular ultrasonography was used to determine brachial artery, flow-mediated, endothelium-dependent, and nitroglycerin-mediated, endothelium-independent vasodilation. To elucidate potential molecular mechanisms that may account for changes in endothelial function, skin biopsy specimens were assayed for eNOS mRNA, eNOS activity, and nitrotyrosine. Endothelium-dependent vasodilation was less in smokers than nonsmoking control subjects during placebo treatment, 8.0±0.6% versus 12.1±1.1%, (P=0.003). Atorvastatin increased endothelium-dependent vasodilation in smokers to 10.5±1.3% (P=0.017 versus placebo) but did not change endothelium-dependent vasodilation in control subjects (to 11.0±0.8%, P=NS). Endothelium-independent vasodilation did not differ between groups during placebo treatment and was not significantly affected by atorvastatin. Multivariate analysis did not demonstrate any association between baseline lipid levels or the change in lipid levels and endothelium-dependent vasodilation. Cutaneous nitrotyrosine levels and skin microvessel eNOS mRNA, but not ENOS activity, were increased in smokers compared with controls but unaffected by atorvastatin treatment. Atorvastatin restores endothelium-dependent vasodilation in normocholesterolemic cigarette smokers independent of changes in lipids. These results are consistent with a lipid-independent vascular benefit of statins but could not be explained by changes in eNOS message and tissue oxidative stress. These findings implicate a potential role for statin therapy to restore endothelial function and thereby investigate vascular disease in cigarette smokers.

Key Words: cigarette smoking • endothelial nitric oxide synthase • hydroxymethylglutaryl CoA reductase inhibitor • endothelial function • oxidative stress

This article has been cited by other articles:

				C. Vlachopoulos, K. Aznaouridis, A. Dagre, C. Vasiliadou, C. Masoura, E. Stefanadi, J. Skoumas, C. Pitsavos, and C. Stefanadis Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects Eur. Heart J., September 1, 2007; 28(17): 2102 - 2109. [Abstract] [Full Text] [PDF]

				J. A. Beckman Does Cuff Location for FMD Matter in Smokers? Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): e140 - e140. [Full Text] [PDF]

				H. Sourij, R. Zweiker, and T. C. Wascher Effects of Pioglitazone on Endothelial Function, Insulin Sensitivity, and Glucose Control in Subjects With Coronary Artery Disease and New-Onset Type 2 Diabetes Diabetes Care, May 1, 2006; 29(5): 1039 - 1045. [Abstract] [Full Text] [PDF]

				K. Iwakura, H. Ito, S. Kawano, A. Okamura, T. Kurotobi, M. Date, K. Inoue, and K. Fujii Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction Eur. Heart J., March 1, 2006; 27(5): 534 - 539. [Abstract] [Full Text] [PDF]

				T. S. Perlstein and R. T. Lee Smoking, Metalloproteinases, and Vascular Disease Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 250 - 256. [Abstract] [Full Text] [PDF]

				H. Ou, Y. H. Shen, B. Utama, J. Wang, X. Wang, J. Coselli, and X. L. Wang Effect of Nuclear Actin on Endothelial Nitric Oxide Synthase Expression Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2509 - 2514. [Abstract] [Full Text] [PDF]

				R. T. Yan, T. J. Anderson, F. Charbonneau, L. Title, S. Verma, E. Lonn, and on behalf of the FATE Investigators Relationship Between Carotid Artery Intima-Media Thickness and Brachial Artery Flow-Mediated Dilation in Middle-Aged Healthy Men J. Am. Coll. Cardiol., June 21, 2005; 45(12): 1980 - 1986. [Abstract] [Full Text] [PDF]